Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of JZB05 versus aflibercept in diabetic macular edema
CTR20232741Phase 3Active
- Sponsor
- Jingze Biopharmaceutical
- Start
- Oct 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of aflibercept in diabetic macular edema (DME), sponsored by Jingze Biopharmaceutical. Started Oct 2023; status: active.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on CTR20232741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232741.